CPHI [CHINA PHARMA] 10-Q/A: (Original Filing)

[o Large accelerated filer o Accelerated filer o] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q/A of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q/A of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: December 24, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qaex321063015.htm]

By | 2016-03-28T18:50:31+00:00 December 28th, 2015|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-Q/A: o Large accelerated filer o Accelerated filer o

[o Large accelerated filer o Accelerated filer o] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q/A of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q/A of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: December 24, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qaex321063015.htm]

By | 2016-03-28T18:51:24+00:00 December 28th, 2015|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-Q/A: (Original Filing)

[o Large accelerated filer o Accelerated filer o Non-accelerated filer] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I have reviewed this report on Form 10-Q/A of China Pharma Holdings, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q/A of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: December 24, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qaex321033115.htm]

By | 2016-03-28T18:52:38+00:00 December 28th, 2015|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-K/A: (Original Filing)

[o x x o Large accelerated filer o Accelerated filer o Non-accelerated filer Do not check if a smaller reporting company x Smaller reporting company o x Documents Incorporated by Reference: None. 2 EXPLANATORY NOTE 1. The Company had not properly evaluated whether collectability of revenue was reasonably assured for sales to customers with significantly aged receivable balances and, therefore,] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 30, 2015 (except for Note 1, as to which the date is December 24, 2015) relating to the consolidated financial statements of China Pharma Holdings, Inc.] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I have reviewed this report on Form 10-K/A of China Pharma Holdings, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K/A of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: December 24, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 5 cphi10kaex321123114.htm]

By | 2016-03-28T18:56:06+00:00 December 28th, 2015|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-K/A: o x x o Large accelerated filer o

[o x x o Large accelerated filer o Accelerated filer o Non-accelerated filer Do not check if a smaller reporting company x Smaller reporting company o x Documents Incorporated by Reference: None. 2 EXPLANATORY NOTE 1. The Company had not properly evaluated whether collectability of revenue was reasonably assured for sales to customers with significantly aged receivable balances and, therefore,] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 30, 2015 (except for Note 1, as to which the date is December 24, 2015) relating to the consolidated financial statements of China Pharma Holdings, Inc.] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I have reviewed this report on Form 10-K/A of China Pharma Holdings, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K/A of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: December 24, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 5 cphi10kaex321123114.htm]

By | 2016-03-28T18:57:23+00:00 December 28th, 2015|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[SKYSTAR BIO-PHARMACEUTICAL COMPANY ANNOUNCES DELISTING FROM NASDAQ Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that on December 17, 2015, Skystar Bio-Pharmaceutical Company (the “Company”) received notification from The Nasdaq Stock Market (“Nasdaq”) informing the Company that a Nasdaq hearing panel had decided to delist the Company’s shares from] []

By | 2016-03-27T14:56:52+00:00 December 18th, 2015|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments
Read More
Skip to toolbar